ADMA.US ADMA Biologics Inc

Healthcare Biotechnology USA Stocks
13.24 USD
Close of Nov 12, 2026
7.21 20.46
Market cap
USD 2.94B
P/E
17.2x
P/B
6.67x
ROE
40.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ADMA.US undervalued?

Graham number
Price13.24
Graham value5.86
Premium125.8%

ADMA.US trades 125.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ADMA Biologics Inc fundamental analysis

No fundamental analysis for ADMA Biologics Inc yet.

ADMA Biologics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVI…

Full company profile